Total antibodies specific to SARS-CoV-2 were detected using electrochemiluminescence assays on the automated Roche cobas e801 analysers based at Public Health England (PHE) Porton. Calibration and quality control were performed as recommended by the manufacturer. Anti-nucleocapsid protein (NP) antibodies were detected using the qualitative Roche Elecsys® AntiSARS-CoV-2 ECLIA (COV2, Product code: 09203079190), whilst anti-spike (S) antibodies were detected using the quantitative Roche Elecsys® Anti-SARS-CoV-2 S ECLIA (COV2 S, Product code 09289275190. Anti-nucleocapsid results are expressed as cut-off index (COI) value, with a COI value of ≥1.0 considered positive for anti-nucleocapsid antibodies. Anti-spike results are expressed as units per mL (AU/mL), with samples with a result of ≥0.8 AU/mL considered positive for anti-spike antibodies within the fully quantitative range of the assay: 0.4–2,500 AU/mL. Samples >2,500 AU/mL were diluted further (1:100) to within the quantitative range.
Cobas e801 analysers
Manufactured by Roche
Sourced in Germany
The Cobas e801 analyser is a compact, automated clinical chemistry analyser designed for in-vitro diagnostic testing. It is capable of performing a wide range of immunoassay tests, including those for hormones, infectious diseases, and therapeutic drug monitoring. The Cobas e801 is designed for high-throughput laboratories, offering efficient sample processing and rapid results.
Automatically generated - may contain errors
3 protocols using cobas e801 analysers
1
SARS-CoV-2 Antibody Detection Protocol
2
Thyroid and Electrolyte Analysis in Prisoners
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
In the first phase, prisoners were screened for TSH and potassium levels. Blood samples were collected at Buddhachinaraj Hospital and Wang Tong Hospital in Phitsanulok province, Thailand. TSH was measured using a chemiluminescent immunoassay.
A complete laboratory investigation, for each person, including blood tests, was collected and kept at −80°C. The urine electrolyte was collected at 50 mL. The samples were performed at King Chulalongkorn Memorial Hospital.
Serum and urine urea nitrogen, creatinine, sodium, potassium, chloride and carbon dioxide were measured using Alinity (Abbott Diagnostics, Chicago, Illinois, USA). Serum calcium, phosphate and magnesium were measured using Alinity (Abbott Diagnostics). Serum and urine osmolarities were measured using an Advanced Instruments Model 3250 single-sample osmometer (Fisher Scientific, Hampton, New Hampshire, USA). Thyroid function tests, including free triiodothyronine (T3), free thyroxine (T4) and TSH, were completed using Alinity I, which was a chemiluminescent microparticle immunoassay (Abbott Diagnostics). Serum thyroglobulin was measured using an electrochemiluminescence immunoassay using the Elecsys Tg II assay and Cobas e 801 analysers (Roche Diagnostics, Mannheim, Germany).
A complete laboratory investigation, for each person, including blood tests, was collected and kept at −80°C. The urine electrolyte was collected at 50 mL. The samples were performed at King Chulalongkorn Memorial Hospital.
Serum and urine urea nitrogen, creatinine, sodium, potassium, chloride and carbon dioxide were measured using Alinity (Abbott Diagnostics, Chicago, Illinois, USA). Serum calcium, phosphate and magnesium were measured using Alinity (Abbott Diagnostics). Serum and urine osmolarities were measured using an Advanced Instruments Model 3250 single-sample osmometer (Fisher Scientific, Hampton, New Hampshire, USA). Thyroid function tests, including free triiodothyronine (T3), free thyroxine (T4) and TSH, were completed using Alinity I, which was a chemiluminescent microparticle immunoassay (Abbott Diagnostics). Serum thyroglobulin was measured using an electrochemiluminescence immunoassay using the Elecsys Tg II assay and Cobas e 801 analysers (Roche Diagnostics, Mannheim, Germany).
3
Quantitative SARS-CoV-2 Antibody Assays
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Total antibodies specific to SARS-CoV-2 were detected using electrochemiluminescence assays on the automated Roche cobas e801 analysers based at Public Health England (PHE) Porton. Calibration and quality control were performed as recommended by the manufacturer. Anti-nucleocapsid protein (NP) antibodies were detected using the qualitative Roche Elecsys® AntiSARS-CoV-2 ECLIA (COV2, Product code: 09203079190), whilst anti-spike (S) antibodies were detected using the quantitative Roche Elecsys® Anti-SARS-CoV-2 S ECLIA (COV2 S, Product code 09289275190), as previously described [13 ]. Anti-nucleocapsid results are expressed as cut-off index (COI) value, with a COI value of ≥1.0 considered positive for anti-nucleocapsid antibodies. Anti-spike results are expressed as units per ml (u/ml), with samples with a result of ≥0.8 U/ml considered positive for anti-spike antibodies within the fully quantitative range of the assay: 0.4–2500 u/ml. Samples > 2500 u/ml were diluted further (1:10, 1:100 and 1:1000) to within the quantitative range.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!